Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread to other organs – metastasize –. But the causes of this association are ...

A team led by the Spanish National Cancer Research Centre (CNIO) has shown in mice that a high-fat diet increases metastasis of triple-negative breast cancer, which has the worst prognosis.

Colorectal cancer is rising in younger adults, and early signs shouldn't be ignored. Healthy habits and timely screening are ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually.

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...